Pipeline

Nobelpharma committed to development of critical but neglected drugs in order to fulfill social mandate

We have constantly been aspiring to conduct research and development of drugs, that are not the prime targets for many pharmaceutical companies due to questionable economic viability with a small number of patients (drugs for unmet medical needs). Our development pipeline mainly includes the drugs such as orphan drugs (drugs for rare diseases) that have been strongly requested by patients, academic societies, or the government, as well as off-label drugs and pediatric medicines. The efficient research and development processes by our small but highly capable organization is what enables us to obtain approvals for such drugs with a comparatively small market size.
While we heretofore have engaged in the development of many unapproved drugs, that were already available in US and Europe but were not developed in Japan despite their significant need, we will also actively take on the challenges of research and development under new and different concepts.

Development Process of Nobelpharma

Development Process of Nobelpharma

Future Development Projects

New Drugs/New Devices

As of June 2020

Compound Expected
Indication
Partner Phase Expected
Approval
NPC-09
N-acetylneuraminic acid
distal myopathy in-house P-II/III -
NPC-21
CMV antibody
CMV infection Evec P-I -
NPC-22
scopolamine
hypersalivation Kitasato Univ P-I -

Life Cycle Management

As of June 2020

Compound Expected
Indication
Partner Phase Expected
Approval
NPC-02
Nobelzin
pediatric formulation
(new formualtion)
National Center for Child Health and Development filed Dec 2020
NPC-05
Unitalc
Nagoya Medical Center
Expected Approval: Jun 2022
Nagoya Medical Center P-II Jun 2022
NPC-06
Fostoin
neural field
(new indication)
Pfizer / in-house P-II -
NPC-12
Rapalimus
intractable vascular/lymphatic discorder
(new indication)
Gifu Univ P-III Jun 2021
NPC-12
Rapalimus
fibrodysplasia ossificans progressive
(new indication)
Kyoto Univ P-II/III Mar 2022
NPC-12
Rapalimus
Pendred syndrome
(new indication)
Keio Univ P-I/IIa Dec 2021
NPC-12
Rapalimus
epilepsy with focal cortical dysplasia type II
(new indication)
Showa Univ P-II -
NPC-12
Rapalimus
idiopathic multicentric Castleman disease
(new indication)
Nagasaki Univ P-II -
NPC-12G
Rapalimus Gel
neurofibromatosis type I Osaka Univ / in-house P-II/III Sep 2022

Overseas Development

As of June 2020

Compound Expected
Indication
Partner Phase Expected MA
NPC-12G
topical silorimus
(Rapalimus Gel)
angiofibroma - US filed Dec 2020
CH filed Aug 2020
EU filing -
NPC-19
(NPC-SE36)
malaria vaccine
prevention of falciparum malaria Osaka Univ
GHIT
P-Ib -
NPC-18
bFGF(Retympa)
tympanic perforation MEEI/Harvard Univ P-II -
NPC-17
thyroid cartilage fixation device
(TITANBRIDGE)
adductor spasmodic dysphonia Nagoya City Univ trial in preparation -
  • Note: Indicagtions and Approval are merely the expectations.
Research and Development

R&D of Nobelpharma

Pipeline

Products

PAGE TOP
  1. HOME
  2. Research and Development
  3. Pipeline